NCT00253266

Venlafaxine Augmentation in Treatment Resistant Depression

Comparison of Venlafaxine Augmentation With Quetiapine v.s. Placebo in Treatment Resistant Depression

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 126 (actual)
• Sponsor: Max-Planck-Institute of Psychiatry · Academic / Other
• Sex: All
• Age: 20 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is an assessment of the efficacy of venlafaxine-HCL augmentation with the neuroleptic quetiapine in treatment resistant depression.

Detailed description

We examine the efficacy of Venlafaxine-HCL augmentation with the neuroleptic Quetiapine in treatment resistant depression in a double-blind randomized clinical trial. Secondary objective is the evaluation of pharmacogenetic factors contributing to drug efficacy in treatment resistant depression.

Conditions

• Depression

Interventions

Type	Name	Description
DRUG	Venlafaxine	Venlafaxine XR up to 450 mg/d during the complete trial (8 weeks)
DRUG	Quetiapine	Quetiapine up to 200 mg/d for four weeks

Timeline

• Start date: 2008-04-01
• Primary completion: 2014-04-01
• Completion: 2014-08-01
• First posted: 2005-11-15
• Last updated: 2015-04-08

Locations

1 site across 1 country: Germany